Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

ClinicalTrials.gov ID: NCT06641089

Public ClinicalTrials.gov record NCT06641089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.

Study identification

NCT ID
NCT06641089
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 15, 2024 (Actual)
Primary completion
Jan 4, 2027 (Estimated)
Completion
Sep 13, 2027 (Estimated)
Last update posted
Oct 9, 2026

2024 – 2027

United States locations

U.S. sites
44
U.S. states
18
U.S. cities
44
Facility City State ZIP Site status
Clinical Site Avondale Arizona 85392 —
Clinical Site Chandler Arizona 85225 —
Clinical Site Flagstaff Arizona 86001 —
Clinical Site Mesa Arizona 85210 —
Clinical Site Phoenix Arizona 85032 —
Clinical Site Scottsdale Arizona 85260 —
Clinical Site Tucson Arizona 85748 —
Clinical Site Jonesboro Arkansas 72401 —
Clinical Site La Jolla California 92037 —
Clinical Site Pomona California 91767 —
Clinical Site San Diego California 92108 —
Clinical Site Santa Monica California 90404 —
Clinical Site Thousand Oaks California 91360 —
Clinical Site Upland California 91786 —
Clinical Site Avon Park Florida 33825 —
Clinical Site Clearwater Florida 33765 —
Clinical Site Hialeah Florida 33016 —
Clinical Site Miami Gardens Florida 33014 —
Clinical Site Tampa Florida 33607 —
Clinical Site Zephyrhills Florida 33542 —
Clinical Site Gainesville Georgia 30501 —
Clinical Site Springfield Illinois 62702 —
Clinical Site Lake Charles Louisiana 70605 —
Clinical Site Baltimore Maryland 21224-6821 —
Clinical Site Grand Blanc Michigan 48439-2451 —
Clinical Site Brooklyn New York 11201 —
Clinical Site Rochester New York 14642 —
Clinical Site Charlotte North Carolina 28262 —
Clinical Site Leland North Carolina 28451 —
Clinical Site Middleburg Heights Ohio 44130 —
Clinical Site Portland Oregon 97239 —
Clinical Site Duncansville Pennsylvania 16635 —
Clinical Site Jackson Tennessee 38305 —
Clinical Site Memphis Tennessee 38119 —
Clinical Site Murfreesboro Tennessee 37128 —
Clinical Site Allen Texas 75013 —
Clinical Site Austin Texas 78745 —
Clinical Site Baytown Texas 77521 —
Clinical Site Colleyville Texas 76034 —
Clinical Site Houston Texas 77089 —
Clinical Site Lubbock Texas 79424 —
Clinical Site Plano Texas 75024 —
Clinical Site Seattle Washington 98122 —
Clinical Site Beckley West Virginia 25801 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06641089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2026 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06641089 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →